MVA-BN-Filo

AXP000201.1 · Vaccine

Platform
MVA-BN
Targets
Zaire ebolavirus GP; Sudan ebolavirus GP; Tai Forest ebolavirus NP; Marburg virus GP
Originator
Bavarian Nordic
Sponsor
Janssen-Cilag International

Names

NameTypeSource
MVA-BN-Filopreferred name, codecurator, curator
Mvabeabrandcurator

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA-BN
Replication
non replicating
Modifications
filovirus glycoprotein and nucleoprotein cassettes inserted into MVA-BN
Transgenes
Zaire ebolavirus GP (Mayinga), Sudan ebolavirus GP (Gulu), Tai Forest ebolavirus NP, Marburg virus GP (Musoke)
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2020-07-01withdrawnMvabeaActive immunisation against Ebola virus disease (Zaire ebolavirus) from 1 year of age, as part of the Zabdeno/Mvabea regimen; authorised under exceptional circumstances and withdrawn 1 May 2026 at the holder's requestsource

Clinical trials (22)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCRecruitingPhase 32025-02-252026-10624Ebola Virus Disease
NCT05284097Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone StudyCompletedPhase 22022-09-192023-03-02133Ebola; Filoviridae Infections; Hemorrhagic Fever, Ebola; Hemorrhagic Fevers, Viral; Immunologic Factors; Infections; Mononegavirales Infections; Physiological Effects of Drugs; RNA Virus Infections; Vaccines; Virus Diseases
NCT05064956Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)CompletedPhase 22021-10-062021-11-1726Ebola; Ebola Virus Disease; Hiv
NCT04711356Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)CompletedPhase 22021-07-082021-09-1750Ebola Virus Disease
NCT04556526A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenCompletedPhase 32020-10-052023-03-024031Healthy
NCT04228783A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsCompletedPhase 32020-02-182022-04-25974Ebola
NCT04152486Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCUnknownPhase 32019-11-142022-01-3120426Ebola Virus Disease
NCT03929757A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in InfantsCompletedPhase 22019-08-192022-08-22108Ebola Virus Disease
NCT04028349ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)CompletedPhase 22019-08-012021-03-19800Ebola Virus Disease
NCT02876328Partnership for Research on Ebola VACcinationsCompletedPhase 22017-03-272019-12-244789Ebola Virus Disease
NCT02860650A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy AdultsCompletedPhase 12016-082017-0572Healthy
NCT02661464Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-FiloTerminatedPhase 32016-05-312021-12-13677Hemorrhagic Fever, Ebola
NCT02598388Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-FiloCompletedPhase 22015-12-102018-12-12578Hemorrhagic Fever, Ebola
NCT02564523Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) AdultsCompletedPhase 22015-11-062019-02-121075Hemorrhagic Fever, Ebola
NCT02509494Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloCompletedPhase 32015-09-302019-06-281023Ebola Virus Disease
NCT02543567A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsCompletedPhase 32015-09-212016-06-07525Healthy
NCT02543268A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsCompletedPhase 32015-09-212016-01-22329Healthy
NCT02416453A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsCompletedPhase 22015-06-152018-01-19423Ebola Viral Disease
NCT02376400A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedPhase 12015-042015-1278Healthy
NCT02376426A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedPhase 12015-032015-0972Healthy
NCT02325050A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedPhase 12015-01-082015-07-02164Healthy
NCT02313077A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedPhase 12014-12-172015-04-1787Healthy

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41616038Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial.PLoS neglected tropical diseases2026cited by trial NCT02876328
PMID 42061096A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.EBioMedicine2026name in abstract: MVA-BN-Filo
PMID 42326817Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.medRxiv : the preprint server for health sciences2026cited by trial NCT02876328
PMID 39012798Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.The Journal of infectious diseases2025cited by trial NCT02416453
PMID 39559990Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.Emerging microbes & infections2025cited by trial NCT02876328
PMID 40921806Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.Nature medicine2025cited by trial NCT04556526
PMID 37673423Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.The Journal of infectious diseases2024name in title: MVA-BN-Filo
PMID 37967326Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2024cited by trial NCT02876328
PMID 38400193Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.Vaccines2024cited by trial NCT02661464
PMID 38523332Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.Human vaccines & immunotherapeutics2024name in title: MVA-BN-Filo
PMID 38552653Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.The Lancet. Infectious diseases2024name in title: MVA-BN-Filo
PMID 38603720Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.PLoS neglected tropical diseases2024cited by trial NCT02416453
PMID 38657084Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2024cited by trial NCT02598388
PMID 38793748Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.Vaccines2024cited by trial NCT02598388
PMID 39040106Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.Frontiers in immunology2024name in abstract: MVA-BN-Filo
PMID 39227399Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.Nature communications2024cited by trial NCT02876328
PMID 36273490Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.The Lancet. Infectious diseases2023cited by trial NCT04711356
PMID 37099841Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.EBioMedicine2023name in abstract: MVA-BN-Filo
PMID 37631885The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.Vaccines2023cited by trial NCT02509494
PMID 37858585Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.The Lancet. Global health2023cited by trial NCT03929757
PMID 37981473Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.Vaccine2023cited by trial NCT05064956
PMID 32939546Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.The Journal of infectious diseases2022name in abstract: MVA-BN-Filo
PMID 34529962Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.The Lancet. Infectious diseases2022cited by trial NCT02509494
PMID 34529963Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.The Lancet. Infectious diseases2022cited by trial NCT02509494
PMID 35015777Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.PLoS medicine2022cited by trial NCT02564523
PMID 35260458Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.BMJ open2022cited by trial NCT04152486
PMID 35640636Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2022name in title: MVA-BN-Filo
PMID 35725488Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.Trials2022cited by trial NCT04556526
PMID 36197845First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.PloS one2022cited by trial NCT02860650
PMID 36516078Randomized Trial of Vaccines for Zaire Ebola Virus Disease.The New England journal of medicine2022cited by trial NCT02876328
PMID 33217361Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.The Lancet. Infectious diseases2021cited by trial NCT02416453
PMID 33485369Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.Trials2021cited by trial NCT02876328
PMID 34588237Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol.BMJ open2021name in abstract: MVA-BN-Filo
PMID 34714820Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.PLoS medicine2021cited by trial NCT02564523
PMID 34930928Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.NPJ vaccines2021cited by trial NCT02543268
PMID 32315287Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.The Journal of clinical investigation2020cited by trial NCT02313077
PMID 33073737Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.Global health action2020name in title: MVA-BN-Filo
PMID 30796816Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.The Journal of infectious diseases2019cited by trial NCT02376426
PMID 30796818Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.The Journal of infectious diseases2019cited by trial NCT02376400
PMID 29895178EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country.Clinical trials (London, England)2018cited by trial NCT02509494
PMID 27925844A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.Human vaccines & immunotherapeutics2017name in abstract: MVA-BN-Filo
PMID 26546548Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.The Lancet. Infectious diseases2016name in title: MVA-BN-Filo
PMID 27092831Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.JAMA2016cited by trial NCT02313077

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41176150Immunogenicity and safety of Ebola vaccines in children: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026name in abstract: MVA-BN-Filo
PMID 41519695Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease.BMC infectious diseases2026name in abstract: Mvabea
PMID 42245043Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.medRxiv : the preprint server for health sciences2026name in abstract: MVA-BN-Filo
PMID 42506625Implementation of a Large-Scale Ebola Vaccination Campaign in Rwanda.Vaccines2026name in abstract: MVA-BN-Filo
PMID 42941682Ebola Virus Disease in Pregnancy: Maternal-Fetal Outcomes, Vertical Transmission, and Implications for Vaccination-A Narrative Review.Journal of clinical medicine2026name in abstract: MVA-BN-Filo
PMID 39932900Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.PLoS medicine2025name in abstract: MVA-BN-Filo
PMID 40173257Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.Science translational medicine2025name in abstract: MVA-BN-Filo
PMID 40337393Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.Annals of medicine and surgery (2012)2025name in abstract: MVA-BN-Filo
PMID 40634393Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.Nature communications2025name in abstract: MVA-BN-Filo
PMID 40934735Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo.Vaccine2025name in abstract: MVA-BN-Filo
PMID 37722397Prevention and post-exposure management of occupational exposure to Ebola virus.The Lancet. Infectious diseases2024name in abstract: MVA-BN-Filo
PMID 38410448A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure.bioRxiv : the preprint server for biology2024name in abstract: Mvabea
PMID 38526137Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions1.Emerging infectious diseases2024name in abstract: MVA-BN-Filo
PMID 38662631Use of Ebola Vaccines - Worldwide, 2021-2023.MMWR. Morbidity and mortality weekly report2024name in abstract: MVA-BN-Filo
PMID 39203952Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo.Vaccines2024name in abstract: MVA-BN-Filo
PMID 39203955Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.Vaccines2024name in title: MVA-BN-Filo
PMID 39715748A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.NPJ vaccines2024name in abstract: MVA-BN-Filo
PMID 35776140Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.The Journal of infectious diseases2023name in title: MVA-BN-Filo
PMID 37691146Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.Cell reports2023name in title: MVA-BN-Filo
PMID 37727795Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.Frontiers in immunology2023name in abstract: MVA-BN-Filo
PMID 37940656Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ vaccines2023name in title: MVA-BN-Filo
PMID 36016151Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels.Vaccines2022name in abstract: MVA-BN-Filo
PMID 36450746Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ vaccines2022name in title: MVA-BN-Filo
PMID 33077299The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.Vaccine2021name in abstract: MVA-BN-Filo
PMID 33514756Durable natural killer cell responses after heterologous two-dose Ebola vaccination.NPJ vaccines2021name in abstract: MVA-BN-Filo
PMID 33676782Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.Vaccine2021name in abstract: MVA-BN-Filo
PMID 33873076Ebola virus disease: current vaccine solutions.Current opinion in immunology2021name in abstract: MVA-BN-Filo
PMID 34077301Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in Rwanda.Human vaccines & immunotherapeutics2021name in abstract: MVA-BN-Filo
PMID 33335092Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.NPJ vaccines2020name in abstract: MVA-BN-Filo
PMID 31243126Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation.Journal of virology2019name in abstract: MVA-BN-Filo
PMID 31909070Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges.AIMS public health2019name in abstract: MVA-BN-Filo
PMID 29870747Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2018name in title: MVA-BN-Filo

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R56AI192635Evaluation of a pan-Filovirus virus-like particle (VLP) vaccine.CINCINNATI CHILDRENS HOSP MED CTRSINGH, KARNAIL2026–2026name in abstract: MVA-BN-Filo
ZIAAI000936Pathogenesis, Treatment and Prevention of Emerging Infectious DiseasesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLANE, CLIFFORD2025–2025name in abstract: MVA-BN-Filo
P51RR013986IMMUNOGENICITY AND EFFICACY OF MVA-BN-FILO IN AN EBOLA AND A MARBURG MODELTEXAS BIOMEDICAL RESEARCH INSTITUTECARRION, RICARDO2011–2011name in title: MVA-BN-Filo

Notes

Mvabea: MVA-BN encoding Zaire ebolavirus (Mayinga) GP, Sudan ebolavirus (Gulu) GP, Tai Forest ebolavirus nucleoprotein and Marburg virus (Musoke) GP; the boost of the two-dose Zabdeno (Ad26.ZEBOV) / Mvabea regimen. EU marketing authorisation 1 July 2020 under exceptional circumstances; withdrawn 1 May 2026 at the holder's request. Route (intramuscular) not stated on the EPAR page opened, so left empty.

How to cite

MVA-BN-Filo (AXP000201.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000201.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.